Conflict of interest: Nothing to declare.
Improved treatment results of children with B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study
Article first published online: 13 FEB 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 7, pages 1215–1221, July 2014
How to Cite
Tsurusawa, M., Mori, T., Kikuchi, A., Mitsui, T., Sunami, S., Kobayashi, R., Takimoto, T., Saito, A., Watanabe, T., Fujimoto, J., Nakazawa, A., Ohshima, K., Horibe, K. and for the lymphoma committee of the Japanese Pediatric Leukemia/Lymphoma Study Group (2014), Improved treatment results of children with B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr. Blood Cancer, 61: 1215–1221. doi: 10.1002/pbc.24975
- Issue published online: 2 MAY 2014
- Article first published online: 13 FEB 2014
- Manuscript Accepted: 16 JAN 2014
- Manuscript Received: 4 OCT 2013
- Ministry of Health, Labor and Welfare of Japan. Grant Number: H14, H15, H16, H17, H20, H23
Vol. 61, Issue 11, 2144, Article first published online: 21 SEP 2014
- non-Hodgkin lymphoma
Previous Japanese studies of childhood B-cell non-Hodgkin lymphoma (B-NHL) have shown a favorable outcome, though the study size was too small to effectively assess the efficacy and safety of treatment for childhood B-NHL.
We performed a nation-wide prospective B-NHL03 study to assess the efficacy and safety of short-pulse intensive chemotherapy for children with B-NHL. They were stratified into four treatment groups according to disease stage, tumor resectability and bone marrow/CNS involvement: Group 1 with all resected stage I/II, Group 2 with non-resected stage I/II, Group 3 with stage III & CNS-negative stage IV, and Group 4 with CNS-positive stage IV & Burkitt leukemia. Treatment duration was 2 courses for Group 1, 4 courses for Group 2, and 6 courses for Groups 3 and 4, respectively. CNS irradiation was omitted in all patients.
The follow-up time ranged from 0.8 to 88 months, with a median of being 45 months. For 321 patients analyzed in this study, overall survival and event-free survival (EFS) at 4 years was 92.7% and 87.4%, respectively. The 4-year EFS according to treatment group were 94% for Group 1 (n = 17), 98% for Group 2 (n = 103), 84% for Group 3 (n = 111), and 78% for Group 4 (n = 90). There was no significant difference in outcome by histology. Therapy-related death occurred in three patients in remission.
Our nationwide large-scale study resulted in a cure rate above 90% with <1% toxic death in childhood B-NHL. Pediatr Blood Cancer 2014;61:1215–1221. © 2014 Wiley Periodicals, Inc.